• Join
  • Login
  • Contact

Search abstracts

Dose and switching data as signatures for postmarketing ‘learning’

  • At: 2004 FIP Congress in New Orleans (USA)
  • Type: Presentation
  • By: LEUFKENS, Hubert (Utrecht Institute Pharm Sci (UIPS), Pharmacoepidemiology and Pharmacotherapy, Utrecht, Netherlands)
  • Abstract:

    Once a drug has been approved for marketing the ‘experiment’ of prescribing and actual usage of the medicine under normal clinical conditions starts. Drug development is a continuum ranging from fundamental, preclinical, clinical and postmarketing ‘learning’. The choice of the drug, the dose regimen and the duration of use are determined by a


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses